Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Rybak

Showing results (11-20 of 137) with videos related to

Pageof 14
Sort By:
Drug Intelligence & Clinical Pharmacy|June 1, 1986
Combination imipenem-aminoglycoside therapyL M Albrecht, M J Rybak
Drug Intelligence & Clinical Pharmacy|July 1, 1983
Subminimum inhibitory concentrations of antimicrobialsS A Hunt, M J Rybak
Antimicrobial Agents and Chemotherapy|December 1, 1995
Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clotsS L Kang, M J Rybak
Drugs|September 1, 1996
Combination antimicrobial therapy for bacterial infections. Guidelines for the clinicianM J Rybak, B J McGrath
The Annals of Pharmacotherapy|June 1, 1994
Single daily dosing of aminoglycosides: a commentaryJ C Rotschafer, M J Rybak
Emergency Medicine Clinics of North America|December 1, 1983
Pharmacologic interventions in resuscitationS C Boike, M J Rybak
Drug Intelligence & Clinical Pharmacy|January 1, 1986
Individualized adjustment of vancomycin dosage: comparison with two dosage nomogramsM J Rybak, S C Boike
Pharmacotherapy|June 10, 1998
The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobialsL D Dresser, M J Rybak
Pharmacotherapy|October 8, 1999
Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin familyD R Foster, M J Rybak
Clinical Pharmacy|November 1, 1983
Additive toxicity in patients receiving vancomycin and aminoglycosidesM J Rybak, S C Boike
Pageof 14

Showing results (11-20 of 137) with videos related to

Sort By:
Pageof 14
Drug Intelligence & Clinical Pharmacy|June 1, 1986
Combination imipenem-aminoglycoside therapyL M Albrecht, M J Rybak
Drug Intelligence & Clinical Pharmacy|July 1, 1983
Subminimum inhibitory concentrations of antimicrobialsS A Hunt, M J Rybak
Antimicrobial Agents and Chemotherapy|December 1, 1995
Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clotsS L Kang, M J Rybak
Drugs|September 1, 1996
Combination antimicrobial therapy for bacterial infections. Guidelines for the clinicianM J Rybak, B J McGrath
The Annals of Pharmacotherapy|June 1, 1994
Single daily dosing of aminoglycosides: a commentaryJ C Rotschafer, M J Rybak
Emergency Medicine Clinics of North America|December 1, 1983
Pharmacologic interventions in resuscitationS C Boike, M J Rybak
Drug Intelligence & Clinical Pharmacy|January 1, 1986
Individualized adjustment of vancomycin dosage: comparison with two dosage nomogramsM J Rybak, S C Boike
Pharmacotherapy|June 10, 1998
The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobialsL D Dresser, M J Rybak
Pharmacotherapy|October 8, 1999
Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin familyD R Foster, M J Rybak
Clinical Pharmacy|November 1, 1983
Additive toxicity in patients receiving vancomycin and aminoglycosidesM J Rybak, S C Boike
Pageof 14